Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo‐controlled trials

AIM: To assess the impact of pre‐specified patient characteristics on efficacy and safety of subcutaneous tanezumab in patients with osteoarthritis (OA). METHODS: Data were pooled from two (efficacy; N = 1545) or three (safety; N = 1754) phase 3 placebo‐controlled trials. Change from baseline to wee...

Descripción completa

Detalles Bibliográficos
Autores principales: Berenbaum, Francis, Schnitzer, Thomas, Kivitz, Alan, Viktrup, Lars, Johnston, Elizabeth, Yang, Ruoyong, Whalen, Ed, Tive, Leslie, Semel, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285028/
https://www.ncbi.nlm.nih.gov/pubmed/34626502
http://dx.doi.org/10.1111/ijcp.14975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285028/
https://www.ncbi.nlm.nih.gov/pubmed/34626502
http://dx.doi.org/10.1111/ijcp.14975

Ejemplares similares